External Source

Oncimmune Ceo Discusses Latest Large Antibody Research Contract And Profitability Goals

2024 4:54
Synopsis
Oncimmune Holdings PLC CEO Martin Gouldstone discusses the company's recent achievements, including a new $700000 ...

You Might Also Like

Oncimmune CEO discusses latest large antibody research contract and profitability goals 4:54
Oncimmune Ceo Discusses Latest Large Antibody Research Contr...
2024
Interview with CEO Martin Gouldstone of Oncimmune 9:18
Interview With Ceo Martin Gouldstone Of Oncimmune
2024
Review and Renew Napa 2025: Managing Immune-Related AEs in Cancer Treatment - Dr Katy Tsai, UCSF 29:21
Review And Renew Napa 2025: Managing Immune-related Aes In C...
2025
Immune-Related Adverse Events 3:35
Immune-related Adverse Events
2024
Fighting Cancer with Antibodies 1:33
Fighting Cancer With Antibodies
2014
Q&A with Oncimmune CEO, Martin Gouldstone 20:50
Q&a With Oncimmune Ceo, Martin Gouldstone
2024
Immune checkpoint inhibitors: shaping the future of lymphoma 0:37
Immune Checkpoint Inhibitors: Shaping The Future Of Lymphoma
2017
Connecting COVID-19 with Autoimmunity | Stanford DoM Grand Rounds | 16 June 2021 1:00:32
Connecting Covid-19 With Autoimmunity | Stanford Dom Grand R...
2021
Immune Related Adverse Events of Checkpoint Inhibitors 53:29
Immune Related Adverse Events Of Checkpoint Inhibitors
2025
Webinar: Programming Cytokine Sensing: A Blueprint for Durable CAR-T 57:35
Webinar: Programming Cytokine Sensing: A Blueprint For Durab...
2025
Answers from the Experts: Q&A - October 2025 58:26
Answers From The Experts: Q&a - October 2025
2025
Q&A with Oncimmune CEO, Martin Gouldstone 19:06
Q&a With Oncimmune Ceo, Martin Gouldstone
2024
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.